Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report

Edyta Lelonek; Magdalena Dębicka; Joanna Maj; Anita Hryncewicz-Gwóźdź; Łukasz Matusiak

doi:10.5114/dr.2015.53422

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2015
vol. 102

Send email

Copy url:

abstract:

Original paper

Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report

Edyta Lelonek

,

Magdalena Dębicka

,

Joanna Maj

,

Anita Hryncewicz-Gwóźdź

,

Łukasz Matusiak

Przegl Dermatol 2015, 102, 331–335

DOI: https://doi.org/10.5114/dr.2015.53422

Online publish date: 2015/09/22

View full text Get citation

PlumX metrics:

Introduction. Anti-tumor necrosis factor α (anti-TNF-α) antibodies are used to treat immune-mediated inflammatory diseases (IMID), which include inflammatory bowel diseases or psoriasis. In the group of adverse events induced by anti-TNF agents we can observe psoriatic lesions.

Case report. We present two women who in the course of therapy of Crohn's disease with adalimumab (ADA) developed psoriasis. Diagnosis was based on the clinical picture and confirmed by histopathological examination. In the first case, treatment with ADA was continued and topical therapy was started, with a good effect. The second patient abandoned ADA therapy and the skin lesions resolved due to the external treatment, too.

Conclusions. The comorbidity of IMID creates therapeutic difficulties and requires further study to elucidate pathophysiology of these diseases, as well as to clarify the mechanism of action of anti-TNF agents.

keywords:

Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report

Edyta Lelonek , Magdalena Dębicka , Joanna Maj , Anita Hryncewicz-Gwóźdź , Łukasz Matusiak

psoriasis, anti-TNF agents, adalimumab, Crohn’s disease

Edyta Lelonek

,

Magdalena Dębicka

,

Joanna Maj

,

Anita Hryncewicz-Gwóźdź

,

Łukasz Matusiak